Gladstone Foundation Establishes Niche In Heart Research

Bequest by developer turns into $118 million endowment to fund work on the molecular bases of heart disease SAN FRANCISCO -- When Southern California shopping center developer J. David Gladstone died while swimming in the pool of his Hollywood Hills home in 1971, his death got scant notice beyond local real estate circles. Yet today the memory of this obscure businessman lives on among biomedical scientists as the benefactor of the J. David Gladstone Foundation. The spectacular growth and sci

Written byFrederic Golden
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share


Bequest by developer turns into $118 million endowment to fund work on the molecular bases of heart disease
SAN FRANCISCO -- When Southern California shopping center developer J. David Gladstone died while swimming in the pool of his Hollywood Hills home in 1971, his death got scant notice beyond local real estate circles.

Yet today the memory of this obscure businessman lives on among biomedical scientists as the benefactor of the J. David Gladstone Foundation. The spectacular growth and scientific successes of this little-known biomedical research organization provide an instructive example of what can be achieved by private philanthropy without large infusions of federal funding.

Created out of a relatively modest bequest of $8 million in real estate holdings, the foundation now has an endowment of some $118 million. That ranks it among the top 150 foundations in the country, though technically it isn't a foundation at all but rather ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies